Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis
Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis. // Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. – URL: https://www.sciencedirect.com/science/article/pii/S240557942600029X?dgcid=rss_sd_all
Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. https://www.sciencedirect.com/science/article/pii/S240557942600029X?dgcid=rss_sd_all
“Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis.” Journal of Clinical Tuberculosis and Other Mycobacterial Diseases.
@article{article53132,
title = {Therapeutic drug monitoring of first-line anti-tuberculosis drugs: impact of dose modification on plasma drug concentrations in pulmonary and extrapulmonary tuberculosis},
journal = {Journal of Clinical Tuberculosis and Other Mycobacterial Diseases},
url = {https://www.sciencedirect.com/science/article/pii/S240557942600029X?dgcid=rss_sd_all}
}
ABSTRACT Background Aspergillus fumigatus can cause life‐threatening infections, primarily treated with azole antifungals. Azole‐resistant A. fumigatus (ARAF) is a major clinical concern. Environmental resistance development is an...
ABSTRACT Background The lipid‐dependent yeast genus Malassezia is composed of skin commensals that can become pathogenic. This genus can cause bloodstream infection in low‐weight preterm neonates and immunocompromised adults. However,...